Small study affirms Avastin as AMD treatment

Here's some vindication for all the ophthalmologists who've been fighting for continued access to Roche's cancer drug Avastin. A small study in wet age-related macular degeneration patients pitting Avastin against the company's designated wet AMD drug Lucentis found that both drugs worked equally well, Boston University researchers say. "[V]isual and anatomic outcomes at one year failed to show a significant difference between both groups," lead author Manju Subramanian says in a statement.

The study enrolled only 22 patients, so it's not exactly definitive. Genentech immediately jumped on the results, saying that they aren't statistically significant. But the researchers say their results warrant further study, at the very least. Luckily, the National Institutes of Health has been conducting a head-to-head study of the two drugs in macular degeneration.

The Avastin-versus-Lucentis debate has a considerable history. Although Lucentis is FDA-approved to treat wet AMD, it's some $2,000 per injection. So price-conscious eye doctors have been using Avastin, which, when administered in the small quantities needed to treat the eyes, costs only about $50 per treatment.

Avastin isn't FDA-approved for the use, and with Lucentis for sale, Roche has no incentive to seek the agency's OK. Genentech (now owned by Roche) tried to tighten up its distribution channels to keep ophthalmologists from using Avastin, but the ensuing outcry from doctors and patients prompted the company to back off a bit. The NIH began its study in 2008, and researchers are expected to finish collecting data by the end of 2010, with final results to come in 2012.

- get the release from Boston University Medical Center
- see the Los Angeles Times story
- read the San Francisco Business Journal piece
- see the study status at ClinicalTrials.gov

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.